Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours

Medicine and Dentistry

• Solid Malignant Neoplasm 100%
• Wnt Signaling 100%
• Tumor 100%
• Diseases 50%
• Clinical Trial 50%
• Immunocompetent Cell 50%
• Biological Marker 50%
• Adverse Event 50%
• Skin Biopsy 50%
• Reverse Transcription Polymerase Chain Reaction 50%
• Response Evaluation Criteria in Solid Tumors 50%
• Tumor Biopsy 50%
• Parageusia 50%
• Recommended Drug Dose 50%
• Oral 50%

Immunology and Microbiology

• Wnt Signaling 100%
• Porcupine 100%
• Immunocompetent Cell 50%
• Reverse Transcription Polymerase Chain Reaction 50%
• Maximum Tolerated Dose 50%
• Recommended Drug Dose 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Solid Malignant Neoplasm 100%
• Porcupine 100%
• Clinical Trial 33%
• Diseases 33%
• Biological Marker 33%
• Adverse Event 33%
• Maximum Tolerated Dose 33%
• Dysgeusia 33%